Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board

Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTC Markets: SIGY) has appointed Dr. Alexander S. Yevzlin to its Scientific Advisory Board. Dr. Yevzlin, a leader in Interventional Nephrology, brings extensive experience from his academic and clinical background to advance Sigyn Therapy, a blood purification technology targeting life-threatening inflammatory disorders, including sepsis. His contributions are expected to aid in the clinical advancement of this innovative therapy. Sigyn Therapy aims to address various critical conditions, enhancing the company's focus on significant health challenges.

Positive

• Appointment of Dr. Alexander S. Yevzlin strengthens the Scientific Advisory Board with expertise in Interventional Nephrology.
• Expected contributions from Dr. Yevzlin may enhance the clinical advancement of Sigyn Therapy.
• Sigyn Therapy addresses significant health challenges such as sepsis, potentially expanding market opportunities.

Negative

• None.

SAN DIEGO, CA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis and other life-threatening disorders, today announced the appointment of Alexander S. Yevzlin, MD, FASN to its Scientific Advisory Board. Dr. Yevzlin’s considerable extracorporeal industry experience and insight is expected to contribute to the clinical advancement of Sigyn Therapy.

Sigyn Therapy is an extracorporeal blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide.

Beyond establishing a novel strategy to combat sepsis, the candidate treatment indications for Sigyn Therapy include, but are not limited to; emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases. 

Dr. Yevzlin graduated magna cum laude from Dartmouth College. He did his residency in Internal Medicine at the University of Michigan and fellowship in Nephrology at Northwestern. Dr. Yevzlin is currently Professor of Medicine and director of Interventional Nephrology at the University of Michigan. Dr. Yevzlin has presented and published over 150 abstracts, invited lectures, and manuscripts. He is an internationally recognized leader in the field of Interventional Nephrology, having edited the first three textbooks on the subject, and is a past President of the American Society of Diagnostic and Interventional Nephrology. In addition to his academic contributions, Dr. Yevzlin has been involved in the invention, design, and reduction to practice of multiple medical devices in his role as chief medical officer, chief science officer, and founder of multiple start-up biotech companies.

About Sigyn Therapeutics™

Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide. Sigyn Therapy™ is a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream. 

To learn more, visit www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties.  Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Stephen Kilmer
Sigyn Therapeutics, Inc.
Investor Relations
(646) 274-3580
stephen@sigyntherapeutics.com

Media Contacts:

Russo Partners, LLC

David Schull
(212) 845-4271
David.Schull@russopartnersllc.com

Nic Johnson
(212) 845-4242
Nic.Johnson@russopartnersllc.com

FAQ

Who is Dr. Alexander S. Yevzlin and what is his role at Sigyn Therapeutics?

Dr. Alexander S. Yevzlin is a notable expert in Interventional Nephrology appointed to the Scientific Advisory Board of Sigyn Therapeutics, focusing on the clinical advancement of Sigyn Therapy.

What is Sigyn Therapy and how does it aim to treat sepsis?

Sigyn Therapy is a blood purification technology designed to treat life-threatening inflammatory disorders, including sepsis, by eliminating pathogen sources and inflammatory mediators from the bloodstream.

What are the potential benefits of Dr. Yevzlin's appointment for Sigyn Therapeutics?

Dr. Yevzlin's appointment is expected to bring valuable insights and advancements in the clinical efficacy of Sigyn Therapy, aiding in its development and potential market success.

What conditions are targeted by Sigyn Therapy?

Sigyn Therapy aims to combat various life-threatening conditions, including sepsis, hepatic encephalopathy, and community-acquired pneumonia, among others.

What is the significance of addressing sepsis in healthcare?

Sepsis is the leading cause of hospital deaths worldwide, making effective treatments like Sigyn Therapy crucial for improving patient outcomes and addressing a major healthcare challenge.